Blueprint
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
____________________________________________________________
Date of
Report (Date of earliest event reported): July 11, 2017
MEDOVEX CORP.
(Exact
Name of Registrant as Specified in Charter)
|
Nevada
|
|
001-36763
|
|
46-3312262
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission File
Number)
|
|
(IRS
Employer Identification No.)
|
|
|
|
|
|
|
|
1950
Airport Road, Suite A
Atlanta,
Georgia
|
|
|
|
30341
|
|
(Address of
principal executive offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (844) 633-6839
____________________________________________________________
Copies
to:
Harvey
Kesner, Esq.
Arthur
S. Marcus, Esq.
Sichenzia
Ross Friedman Kesner LLP
61
Broadway, 32nd Floor
New
York, New York 10006
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
□
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
□
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
2(b))
□
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 7.01 Regulation FD
Disclosure
On July 11, 2017, Medovex Corp. (the “Company”) issued a new investor presentation, a
copy of which is attached hereto as Exhibit
99.1.
The information contained in this Current Report on Form 8-K shall
not be deemed “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“Exchange Act”), or incorporated by reference in any
filing under the Securities Act of 1933, as amended (the
“Securities
Act”) or the Exchange
Act, except as shall be expressly set forth by specific reference
in such a filing. The furnishing of the information in
this Current Report on Form 8-K is not intended to, and does not,
constitute a representation that such furnishing is required by
Regulation FD or that the information contained in this Current
Report on Form 8-K constitutes material investor information that
is not otherwise publicly available.
The Securities and Exchange Commission encourages registrants to
disclose forward-looking information so that investors can better
understand the future prospects of a registrant and make informed
investment decisions. This Current Report on Form 8-K and exhibits
may contain these types of statements, which are
“forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, and which involve
risks, uncertainties and reflect the Registrant’s judgment as
of the date of this Current Report on Form 8-K. Forward-looking
statements may relate to, among other things, operating results and
are indicated by words or phrases such as “expects,”
“should,” “will,” and similar words or
phrases. These statements are subject to inherent uncertainties and
risks that could cause actual results to differ materially from
those anticipated at the date of this Current Report on Form 8-K.
Investors are cautioned not to rely unduly on forward-looking
statements when evaluating the information presented
within.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits.
|
Exhibit No.
|
|
Description
|
|
99.1
|
|
MedoveX
Corp. Investor Presentation dated July 11, 2017
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly
authorized.
|
Date: July
11, 2017
|
MEDOVEX CORPORATION
By: /s/
Jarrett Gorlin
Jarrett Gorlin
Chief Executive Officer
|
|
|
|
